STOCK TITAN
  1. Home
  2. News
  3. VIR

Vir Biotechnology, Inc. - VIR STOCK NEWS

Welcome to our dedicated page for Vir Biotechnology news (Ticker: VIR), a resource for investors and traders seeking the latest updates and insights on Vir Biotechnology stock.

Vir Biotechnology, Inc. (VIR) pioneers immunology solutions targeting complex infectious diseases through innovative platforms including antibody therapies, T cell engineering, and siRNA technology. This dedicated news hub provides investors and industry stakeholders with timely updates on clinical developments, strategic partnerships, and regulatory milestones.

Access authoritative updates on VIR's research pipeline, financial performance announcements, and scientific breakthroughs in infectious disease management. Our curated collection ensures transparent access to press releases spanning clinical trial progress, collaborative initiatives, and patent filings.

Key updates include advancements in hepatitis B/HIV therapies, influenza A research, and platform technology licensing agreements. Bookmark this page to efficiently monitor VIR's contributions to biotechnology and its evolving position in global health innovation.

News

Vir Biotechnology Announces Dr. Phil Pang Will Step Down as Chief Medical Officer

Rhea-AI Summary
Vir Biotechnology, Inc. (Nasdaq: VIR) announced the departure of Chief Medical Officer Dr. Phil Pang in March 2024 to focus on family. The company is searching for a successor. Dr. Pang's contributions to the development of sotrovimab during the COVID-19 pandemic are highlighted. Vir's CEO praised his work in infectious diseases and team building for global health needs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.17%
Tags
none
-
News

Vir Biotechnology to Provide Business Update and Report Fourth Quarter 2023 Financial Results on February 22, 2024

Rhea-AI Summary
Vir Biotechnology, Inc. (Nasdaq: VIR) will release its fourth-quarter financial results on February 22, 2024, and host a conference call to discuss the corporate update. The press release and webcast will be accessible on the company's website. A recorded version of the call will be available for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.93%
Tags
earnings
-
News

Vir Biotechnology Announces Strategic Steps to Reduce Operating Expenses and Focus Investment on Areas with Highest Potential for Value Creation

Rhea-AI Summary
Vir Biotechnology, Inc. (Nasdaq: VIR) is focusing on chronic hepatitis delta and chronic hepatitis B clinical programs and antibody platform to target infectious diseases, autoimmune diseases, and oncology. The company is reducing its workforce by approximately 12% and consolidating its geographic footprint, anticipating annual savings of at least $40 million from cost optimization efforts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.2%
Tags
none
News

Vir Biotechnology to Present at J.P. Morgan 2024 42nd Annual Healthcare Conference

Rhea-AI Summary
Vir Biotechnology, Inc. (Nasdaq: VIR) CEO Marianne De Backer to present at J.P. Morgan 2024 42nd Annual Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.37%
Tags
conferences
-
News

Vir Biotechnology to Present New Data from Its Ongoing Phase 2 Chronic Hepatitis Delta and B Trials Today at AASLD’s The Liver Meeting® 2023

Rhea-AI Summary
Vir Biotechnology, Inc. (Nasdaq: VIR) presents promising data from Phase 2 SOLSTICE and MARCH trials at AASLD The Liver Meeting®. Initial SOLSTICE data showed 100% HDV RNA reduction with combination therapy. MARCH Part B data demonstrated 3x higher HBsAg loss rates with VIR-3434 + VIR-2218 compared to previous treatment. Investor conference call scheduled for November 13th.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.44%
Tags
conferences clinical trial
-
News

Vir Biotechnology to Present Late-Breaking Data from Its Ongoing Phase 2 Chronic Hepatitis B and Delta Trials at AASLD’s The Liver Meeting® 2023

Rhea-AI Summary
VIR Biotechnology, Inc. (Nasdaq: VIR) to present new data from Phase 2 trials evaluating VIR-3434 and VIR-2218 for chronic hepatitis B and chronic hepatitis delta patients at AASLD The Liver Meeting®. Late-breaking presentations include end-of-treatment results after 24 weeks of therapy and preliminary results from the Phase 2 SOLSTICE Trial. Investor conference call scheduled for November 13th at 1:30 p.m. PT / 4:30 p.m. ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.99%
Tags
conferences clinical trial
News

Vir Biotechnology Ranked the Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500™

Rhea-AI Summary
VIR: Vir Biotechnology, Inc. Tops Deloitte Technology Fast 500 List for Second Year, Revenue Growth Fueled by Sotrovimab Sales and Collaboration Partnerships with GSK, Brii Biosciences, and the Bill & Melinda Gates Foundation
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.78%
Tags
none
-
News

Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Rhea-AI Summary
Vir Biotechnology, Inc. provided a corporate update and reported financial results for Q3 2023. The company will present new data at AASLD from Phase 2 clinical trials for chronic hepatitis B and chronic hepatitis delta. They are expanding their focus to autoimmune diseases and immuno-oncology. Jennifer Towne has been appointed as Executive Vice President and Chief Scientific Officer. They secured new BARDA funding for the development of RNA-delivered monoclonal antibodies. As of September 30, 2023, they have $1.7 billion in cash, cash equivalents, and investments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.96%
Tags
earnings
-
News

Vir Biotechnology Appoints Jennifer Towne, Ph.D., as Executive Vice President and Chief Scientific Officer

Rhea-AI Summary
Vir Biotechnology announces the appointment of Jennifer Towne, Ph.D., as Executive Vice President and Chief Scientific Officer. Dr. Towne will lead the company's research function and focus on viral-associated diseases and immune targeting. She brings over two decades of immunology R&D experience and has developed 16 drug candidates throughout her career.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.74%
Tags
management
News

Vir Biotechnology to Participate in the H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Conference

Rhea-AI Summary
Vir Biotechnology's Chief Medical Officer to participate in virtual fireside Q&A at HBV Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.48%
Tags
conferences
Stock VIR logo
Vir Biotechnology, Inc.

Nasdaq:VIR

VIR Rankings

#1751 Ranked by Market Cap
N/A Ranked by Dividends

VIR Stock Data

759.35M
101.72M
12.01%
76.71%
5.66%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
SAN FRANCISCO